Efficacy and safety of dimethyl fumarate in the treatment of multiple sclerosis：a meta-analysis
- VernacularTitle:富马酸二甲酯治疗多发性硬化疗效与安全性的Meta分析
- Author:
Fengyun LI
1
,
2
;
Rui LAN
1
;
Duo ZHAO
1
;
Fugui LIU
1
;
Liangchen CHEN
1
Author Information
1. Dept. of Encephalopathy，the First Affiliated Hospital of Henan University of CM，Zhengzhou 450000，China
2. First Clinical Medical College，Henan University of Chinese Medicine，Zhengzhou 450000，China
- Publication Type:Journal Article
- Keywords:
dimethyl fumarate;
multiple sclerosis;
disease modification treatment;
recurrence rate;
adverse event
- From:
China Pharmacy
2024;35(14):1776-1780
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To evaluate the efficacy and safety of dimethyl fumarate （DMF） in the treatment of multiple sclerosis （MS）. METHODS Retrieved from CBM， Web of Science， PubMed， the Cochrane Library， Embase， CNKI， Wanfang Data， and VIP， randomized controlled trials （RCTs） about DMF （trial group） versus other drugs or placebo （control group） were collected. After data screening and extraction， quality evaluation， meta-analysis was conducted by using RevMan 5.3 software. RESULTS A total of 6 literature were included， involving 638 patients. Results of meta-analysis showed that the proportion of patients with lesion changes after treatment in the trial group was lower than control group [MD＝－0.65， 95%CI（－1.27， －0.02）， P＝0.04]； there was no statistical significance in recurrence rate [RR＝1.06， 95%CI（0.52，2.17）， P＝0.88]， the proportion of patients with new lesions after treatment [RR＝1.05， 95%CI（0.62，1.80）， P＝0.85]， expanded disability status scale after treatment [MD＝0.02，95%CI （－0.18， 0.23）， P＝0.82]， the incidence of adverse events [RR＝1.33， 95%CI（0.97， 1.84）， P＝0.08] or severe adverse events [RR＝0.95，95%CI（0.48，1.90），P＝0.89] between 2 groups. Results of sensitivity analysis showed the study obtained unstable recurrence rate and the incidence of adverse events， while other results were robust. CONCLUSIONS DMF can control the lesion progression in MS patients to some extent and doesn’t increase the incidence of adverse events and serious adverse events， but there is no significant advantage in reducing the recurrence rate and controlling the disability progression.
